Higher BMI is associated with higher expiratory airflow normalised for lung volume (FEF25-75/FVC) in COPD.

Eric Abston  
*University of Iowa*

Alejandro Comellas  
*University of Iowa*

Robert Michael Reed  
*University of Maryland at Baltimore*

*Please see article for additional authors.*
Higher BMI is associated with higher expiratory airflow normalised for lung volume (FEF25–75/FVC) in COPD

Eric Abston,1 Alejandro Comellas1,2 Robert Michael Reed,3 Victor Kim,4 Robert A Wise,5 Roy Brower,5 Spyridon Fortis,1,2 Reinhard Beichel,1,6,7 Surya Bhatt,8 Joseph Zabner,1,2 John Newell,7,9 Eric A Hoffman,1,6,7,9 Michael Eberlein1,2

ABSTRACT

Introduction The obesity paradox in chronic obstructive pulmonary disease (COPD), whereby patients with higher body mass index (BMI) fare better, is poorly understood. Higher BMIs are associated with lower lung volumes and greater lung elastic recoil, a key determinant of expiratory airflow. The forced expiratory flow (25–75) (FEF25–75)/forced vital capacity (FVC) ratio reflects effort-independent expiratory airflow in the context of lung volume and could be modulated by BMI.

Methods We analysed data from the COPDGene study, an observational study of 10,192 subjects, with at least a 10 pack-year smoking history. Data were limited to subjects with BMI 20–40 kg/m² (n=9222). Subjects were stratified according to forced expiratory volume in 1 s (FEV₁) (%predicted)-quintiles. In regression analyses and Cox proportional hazard models, we analysed the association between BMI, the FEF25-75/FVC ratio, the imaging phenotype, COPD exacerbations, hospitalisations and death.

Results There was no correlation between BMI and FEV₁ (%predicted). However, a higher BMI is correlated with a higher FEF25–75/FVC ratio. In CT scans, a higher BMI was associated with less emphysema and less air trapping. In risk-adjusted models, the quintile with the highest FEF25–75/FVC ratio was associated with a 46% lower risk of COPD exacerbations (OR 0.54, p<0.001) and a 40% lower risk of death (HR 0.60, p=0.02), compared with the lowest quintile. BMI was not independently associated with these outcomes.

Conclusions A higher BMI is associated with lower lung volumes and higher expiratory airflows when normalised for lung volume, as quantified by the FEF25–75/FVC-ratio. A higher FEF25–75/FVC-ratio is associated with a lower risk of COPD exacerbations and death and might quantify functional aspects of the paradoxical effect of higher BMIs on COPD.

Key messages

- The obesity-paradox in COPD, whereby patients with higher body mass index (BMI) fare better, is poorly understood.
- In an ancillary study to COPDGene a higher BMI is associated with lower lung volumes and higher expiratory airflows when normalized for lung volume, as quantified by the FEF25–75/FVC-ratio and a higher FEF25–75/FVC-ratio is independently associated with a lower risk of COPD exacerbations and death.
- The FEF25–75/FVC-ratio quantifies functional aspects of the paradoxical effect of BMI on COPD and further understanding of the physiological mechanism could lead to novel non-pharmacological therapies based on the analogies to chest wall strapping.

INTRODUCTION

There exists a poorly understood obesity paradox in chronic obstructive pulmonary disease (COPD), where obese patients with COPD tend to fare better than non-obese patients with similar degree of airflow obstruction. Observational studies show that overweight and obese patients with COPD often have higher FEV₁ (%predicted) and a lower SPIROMETRY (FEV₁/FVC) ratio compared with patients with lower BMI. However, the mechanisms underlying this obesity paradox in COPD are unclear. Higher body mass index (BMI) is associated with lower mortality and fewer hospital admissions. Obesity has also been associated with higher FEF25–75/FVC ratio and a higher FEF25–75/FVC-ratio is independently associated with a lower risk of COPD exacerbations and death.

The mechanisms underlying this obesity paradox in COPD are unclear. Higher body mass index (BMI) in patients with COPD is associated with lower functional residual capacity (FRC) and residual volume (RV), likely related to the mass effects of adipose tissue acting on the chest wall or abdomen. In addition to affecting the chest wall, higher BMI is associated with greater static lung elastic recoil, and in some studies with increased expiratory flow, as lung elastic recoil of the lung is the key determinant of maximal expiratory airflow.

The ratio of mid-vital capacity expiratory airflow (forced expiratory flow (25–75) (FEF25–75)) divided by the forced vital capacity (FVC) corresponds to effort-independent expiratory airflow adjusted for lung volume. We hypothesised that (1) a higher BMI is associated with lower expiratory airflow normalised for lung volume (FEF25–75/FVC) in COPD.


Received 30 June 2017
Revised 4 September 2017
associated with a higher FEF_{25-75}/FVC ratio and (2) that the FEF_{25-75}/FVC ratio, as a possible functional correlate of the physiological effects of obesity, modulates the risk for COPD exacerbations and death.

METHODS

We evaluated data from the COPDGene study—an observational cohort study of 10,192 participants across 21 centres in the USA (2008–2011). Participants were non-Hispanic Whites and African-Americans with at least a 10 pack-year smoking history. Each participant provided informed written consent. The COPDGene protocol has been previously described and is available at www.copdgene.org. Methods pertinent to the data analysed in this study are as follows: subjects completed spirometry according to the American Thoracic Society standards. High-resolution CT scans were performed at full inspiration and at end exhalation. Quantitative measures of emphysema were defined as the percentage of lung volume on the inspiratory CT with attenuation less than −950 Hounsfield units (HU). Gas trapping was defined as the percentage of lung volume on the expiratory CT with attenuation less than −856 HU. The data were limited in this study to subjects with a BMI between 20 and 40 kg/m² (n=9222) in order to limit the effects of spurious values and at physiological extremes of the BMI spectrum. Figure 1 shows a BMI histogram for the entire study population.

The study subjects were stratified according to forced expiratory volume in 1 s (FEV₁) (%predicted)-quintiles. The relationship between BMI, CT-imaging phenotype (CT volumetry, emphysema and air trapping), spirometry (FEV₁, FVC and FEV₁/FVC) and the FEF_{25-75}/FVC ratio for the entire study population and within each FEV₁ (%predicted)-quintile was analysed by Spearman’s rank correlation coefficients (Spearman’s rho) and by using a fractional polynomial approach to evaluate for a possible non-linear association. We used logistic regression to evaluate the relationship between the FEF_{25-75}/FVC ratio, BMI and the occurrence of COPD exacerbations. The outcome variable, COPD exacerbation, was examined as a binary variable. A univariate analysis was performed to assess for variables that were associated with COPD exacerbation at a threshold of p=0.1 as previously described, and those variables identified were then included in stepwise backward multivariate logistic models to adjust for confounders.

To evaluate the relationship between the FEF_{25-75}/FVC ratio, BMI and the occurrence of COPD exacerbations in the study follow-up period, the COPDGene Longitudinal Follow-Up (LFU) dataset was utilised. The LFU dataset consists of telephone survey data obtained every 3–6 months after the initial study. Information on subjects including COPD exacerbations and hospitalisations was obtained. Follow-up COPDGene mortality data were analysed to evaluate the relationship between the FEF_{25-75}/FVC ratio and mortality in the follow-up period. Cox proportional hazard models were used for the mortality analysis. We tested interactions between FEF_{25-75}/FVC ratio and BMI, and the significance of differences between nested models was tested using the likelihood ratio test. Subjects with missing data were excluded from the respective analyses.

RESULTS

Patient demographics including metrics of disease severity, comorbid conditions, imaging parameters and spirometric values is shown in the Table 1 in the online supplementary file 1, stratified by FEV₁ (%predicted)-quintiles. Comorbid conditions were more common in those with more severe COPD. BMI was not significantly different between FEV₁-quintiles. All metrics of disease severity correlated with FEV₁ (%predicted)-quintiles.

No consistent relationship between FEV₁ (%predicted) and BMI were found when analysing the entire sample (p=0.6), or within most FEV₁ (%predicted)-quintiles (figure 2A). However, a higher BMI was associated with lower FVC (%predicted) (figure 2B). Consequently, a higher BMI was associated with higher FEV₁/FVC ratios, both in the whole study population and in each FEV₁ (%predicted)-quintile (p<0.001) (figure 2C). A higher BMI was associated with higher FEF_{25-75} both in the entire study population and in each quintile of FEV₁ (p=0.001) (figure 3A). There was a positive association between the FEF_{25-75}/FVC ratio and BMI, both in the entire study population and in each quintile of FEV₁ (%predicted) (p=0.001) (figure 3B).

A higher BMI was associated with lower total lung capacity (TLC) (%predicted) and functional residual capacity (FRC) (%predicted) derived from CT volumetry (figure 4). A higher BMI correlated inversely with per cent emphysema (p<0.001) within most FEV₁ (%predicted)-quintile and for the entire study population (figure 5A). The slope of the line fitting this association was much steeper in the FEV₁ (%predicted)-quintile...
Figure 2  The relationship between body mass index (BMI) and per cent predicted forced expiratory volume in 1 s (FEV₁, A) and per cent predicted forced vital capacity (FVC) (B) and the FEV₁/FVC ratio (C), stratified by FEV₁ quintiles and for the entire study population (BMI 20–40). Spearman's rank correlation coefficients (Spearman's rho) are shown and significance of the correlation is indicated by the corresponding p value.

with the lowest FEV₁. This indicates that comparatively smaller differences in BMI correlated with much larger differences in emphysema in subjects with more severe disease than in quintiles with a more normal FEV₁. A higher BMI correlated inversely with per cent air trapping (p<0.001) on expiratory CT scans within each FEV₁ (%predicted)-quintile and for the entire study population (figure 5B). This reduction in air trapping with increasing BMI (from 20 to 40) was strongest in the FEV₁ (%predicted)-quintile with the lowest FEV₁.

As the FEF₂₅₋₇₅/FVC ratio could reflect the physiological impact of BMI on lung function we next evaluated
the association between $\text{FEF}_{25-75}/\text{FVC}$ ratio, BMI and clinical outcomes in COPD. In unadjusted models a higher $\text{FEF}_{25-75}/\text{FVC}$ ratio was associated with a lower risk of self-reported COPD exacerbations at study entry and a lower occurrence of COPD exacerbations during the study follow-up period (table 1A). Furthermore, a higher $\text{FEF}_{25-75}/\text{FVC}$ ratio was associated with a lower risk of hospitalisations and a lower risk of death during the study follow-up period. When adjusting for BMI the $\text{FEF}_{25-75}/\text{FVC}$ ratio remained independently associated with the above clinical outcomes, whereas BMI itself did not remain consistently associated with these outcomes (table 1B). In comprehensive risk-adjusted models, a higher $\text{FEF}_{25-75}/\text{FVC}$ ratio remained independently associated with a lower risk of COPD exacerbations, hospitalisation and mortality in the follow-up period.

**DISCUSSION**

In a large cohort of current and former smokers, we found that that FEV$_1$ was largely unaffected by BMI. However, when analysing expiratory airflow in the context of the corresponding lung volumes via the $\text{FEF}_{25-75}/\text{FVC}$ ratio, a positive association between the $\text{FEF}_{25-75}/\text{FVC}$ ratio and BMI became evident. A higher $\text{FEF}_{25-75}/\text{FVC}$ ratio would either predict higher elastic recoil or greater small airway sizes for the same lung volume, and consistent with this we found higher BMI was associated with lesser emphysema and less air trapping. A higher $\text{FEF}_{25-75}/\text{FVC}$ ratio was associated with a lower risk of COPD exacerbations and death and might be a parameter that quantifies possible physiological effects associated with a higher BMI on COPD outcomes.

Classically, FEV$_1$ has been used to quantify the disease severity in COPD. However, FEV$_1$ was not modulated by obesity-related changes in lung function in previous studies, and similarly we did not find a consistent association between BMI and FEV$_1$ in the current study. However, we found a positive correlation between BMI and $\text{FEF}_{25-75}$ and an inverse relation between BMI and FVC. A misclassification of the severity of airflow obstruction by stratifying according to FEV1 (%predicted) could have affected the study results, as a reduction of

![Figure 3](image-url)
lungs volumes due to a restrictive process, like obesity, can add to the reduction in FEV1 from an obstructive disease. Thus, the reduced lung volumes from obesity might lead to an overestimation of the severity of the obstructive process. We performed a sensitivity analysis in which we adjusted the FEV1 (%predicted) by the total lung capacity (TLC) (% predicted), as derived from CT scans at full inspiration. We created FEV1 (%predicted)-adjusted = (FEV1 (%predicted)/TLC (%predicted)). We then restratified subjects according to quintiles of FEV1 (%predicted)-adjusted. This sensitivity analysis showed similar results (see figures 1 and 2 in the online supplementary file 1) and a higher BMI remained associated with a higher FEF25–75/FVC ratio, lesser emphysema and lesser air trapping.

Jere Mead developed a similar ratio (FEF25–75/FVC multiplied by lung elastic recoil) to reflect the size of the airway structure in relation to the lung volume. He used this ratio to express the physiological variation in the geometry of the tracheobronchial tree and lung parenchyma due to different patterns of growth among both genders, which he termed dysanapsis. Thus, the higher FEF25–75/FVC ratio with increasing BMIs we found in this study would either predict higher elastic recoil or larger airway sizes for the same lung volume. A key finding of this study was that, as predicted by the association with a higher FEF25–75/FVC ratio, a higher BMI correlated inversely with per cent air trapping on expiratory CT scans (figure 5B). Air trapping is correlated with the closing volume of small airways and an isolated deflating effect of obesity should not affect the closing volume of small airways. Imaging studies in COPD have demonstrated that small conducting airways narrow and disappear before the onset of emphysematous disease. If it is correct that widespread narrowing and loss of smaller conducting airways precedes the onset of emphysematous destruction, then a possible beneficial effect of obesity on small airway function could reduce the risk for progression to emphysema. Similar to observations made in the Multiethnic Study of Atherosclerosis lung study, we found that a higher BMI was associated with less emphysema (figure 5). This could suggest that obesity modulates small airway function in COPD.
Figure 5  The relationship between body mass index (BMI) and per cent emphysema (A) and per cent air trapping (B), stratified by forced expiratory volume in 1 s (FEV₁) quintiles and for the entire study population (BMI 20–40). Spearman’s rank correlation coefficients (Spearman’s rho) are shown and significance of the correlation is indicated by the corresponding p value.

The effects of obesity on pulmonary physiology have been carefully characterised both in healthy subjects and in those with COPD.9 The most prominent aspect of obesity-induced changes in the respiratory system is the reduction in expiratory reserve volume (ERV), followed by more modest reductions in other lung volumes.10 Obesity also reduces lung compliance and increases lung elastic recoil in several studies.8 10 There are analogies between the effects of obesity on the respiratory system and chest wall strapping (CWS).20–28 CWS is a technique to restrict chest and abdominal wall motion during respiration to force the lung to operate at lower lung volumes.20–28 CWS causes a decrease in lung volumes, an increase in expiratory flows and airway conductance, a decrease in lung compliance and an increase in lung elastic recoil.20–28 CWS reduces TLC by ~35% with similar changes in vital capacity, FRC and similarly to obesity ERV is reduced the most by 50%.20–28 Lung elastic recoil is increased by on average 180%.20 CWS increases mid-vital capacity maximum expiratory flows to on average 150% of prestrapped rates.20 The increased lung elastic recoil from CWS could increase the radial traction on small airways via the interdependence between airways and parenchyma.20 29 30 This increase radial traction could dilate small airways resulting in lower closing volumes and higher airway conductance.20 29 30 Consistent with this possible mechanism, a study of normal subjects and in subjects with mild to moderate COPD showed that CWS increased the number of small airways detectable via an automated CT airway segmentation algorithm.31–33 Furthermore, transplanting significantly oversized donor lungs into a recipient with a smaller chest cavity is conceptually similar to CWS and was associated with higher mid-vital capacity expiratory airflows and higher FEV₁/FVC ratios.20 34–37 The FEV₁/FVC ratio is conceptually also a ‘dysanapsis ratio’. Similar to the FEF₂₅₋₇₅/FVC ratio, the FEV₁/FVC ratio varied with BMI (figure 2C). Thus, a higher BMI could be associated with a normal FEV₁/FVC ratio, even in the presence of obstructive airways disease. This may explain some of the observations regarding the ‘GOLD–Unclassified Smokers’ or ‘preserved ratio impaired spirometry’ phenotype that is characterised by a reduced FEV₁ with a preserved FEV₁/FVC ratio.38 Supporting this possibility, the ‘GOLD–Unclassified
Table 1: The association of FEV 25-75 / FVC ratio and BMI with COPD outcomes

<table>
<thead>
<tr>
<th>Parameter</th>
<th>(A) Model 1, univariate</th>
<th>(B) Model 2, multivariate adjusted (as indicated in legend)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR 95%</td>
<td>p</td>
</tr>
<tr>
<td>Exacerbation* history†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEF&lt;sub&gt;25–75&lt;/sub&gt;/FVC-ratio</td>
<td>Quintile 1 versus 5</td>
<td>0.11</td>
</tr>
<tr>
<td>BMI Quintile 1 versus 5</td>
<td>1.28</td>
<td>1.10 to 1.50</td>
</tr>
<tr>
<td>Exacerbation* on follow up§</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEF&lt;sub&gt;25–75&lt;/sub&gt;/FVC-ratio</td>
<td>Quintile 1 versus 5</td>
<td>0.28</td>
</tr>
<tr>
<td>BMI Quintile 1 versus 5</td>
<td>1.1</td>
<td>0.97 to 1.25</td>
</tr>
<tr>
<td>Hospitalised**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEF&lt;sub&gt;25–75&lt;/sub&gt;/FVC-ratio</td>
<td>Quintile 1 versus 5</td>
<td>0.09</td>
</tr>
<tr>
<td>BMI Quintile 1 versus 5</td>
<td>0.97</td>
<td>0.79 to 1.19</td>
</tr>
<tr>
<td>Mortality††</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEF&lt;sub&gt;25–75&lt;/sub&gt;/FVC-ratio</td>
<td>Quintile 1 versus 5</td>
<td>0.17</td>
</tr>
<tr>
<td>BMI Quintile 1 versus 5</td>
<td>0.62</td>
<td>0.50 to 0.78</td>
</tr>
</tbody>
</table>

*Exacerbation analysis is stratified according to exacerbation yes/no.
†Exacerbation data from first study visit.
‡Adjusted for: BMI, age at enrolment, history of severe exacerbations, chronic bronchitis, asthma, American Thoracic Society (ATS) pack-year smoking, current smoking, fume exposure at work, gastro-oesophageal reflux disease, congestive heart failure, sleep apnoea, history of blood clots, high blood pressure, Modified Medical Research Council dyspnoea scale, St. George’s Respiratory Questionnaire score, forced expiratory volume in 1 s (%predicted) and 6 min walk distance.
§Exacerbation data from longitudinal follow-up data set.
¶Adjusted for: BMI, pack-year smoking, current smoking, oxygen use, per cent emphysema and Body mass index, airflow Obstruction, Dyspnoea and Exercise score.
**Hospitalisation analysis is stratified according to yes/no.
††Complete mortality data were available for 7534 subjects.

BMI, body mass index; FEF<sub>25–75</sub>, forced expiratory flow (25–75); FVC, forced vital capacity.

Smokers’ phenotype was associated with increased BMIs. Smokers’ phenotype was associated with increased BMIs.38

This study was limited in several aspects. Due to the cross-sectional nature of the study, we cannot determine a causal relationship between BMI and the imaging phenotype (lower TLC, FRC, less emphysema and air trapping). While the data is suggestive that obesity could have a CWS-like effect of increasing lung elastic recoil, we do not have measurements of lung elastic recoil or expiratory airflows at isovolume conditions. The FEF<sub>25–75</sub>/FVC ratio has been developed as a surrogate measure of airway size relative to lung size or lung dysanapsis. While FVC can be an appropriate surrogate of lung size in normal lungs, it can be reduced due to forced exhalation in subjects with COPD and emphysema, where FVC can be significantly lower than the slow vital capacity. In a sensitivity analysis, we have generated a ‘dysanapsis’ ratio that instead of FVC included TLC (derived from CT volumetry), as a measurement of lung size. There is close linear relationship between the FEF<sub>25–75</sub>/FVC ratio and the FEF<sub>25–75</sub>/TLC ratio (Spearman’s rho was 0.97, p<0.0001, see figure 3 in the online supplementary file 1). Also, BMI itself is an imperfect metric of adiposity, and different fat distribution patterns can result in varying respiratory effects with similar BMI. As gender can affect both fat distribution patterns and airway structure, we performed a sensitivity analysis stratified by gender, which showed similar results (see figure 4 in the online supplementary file 1). In this study, we limited the BMI to between 20 and 40, which excluded 970 subjects (approximately 10% of the study population). When we analysed the entire study cohort, the overall results were not different (see figures 5 and 6 in the online supplementary file 1). There appears to be a plateau effect to the obesity-induced changes in lung function at the extremes of BMI. Mild to moderate obesity shares the greatest similarities with lung function changes observed with CWS, whereas extreme obesity, especially when FRC or ERV are reduced below certain thresholds can be associated with worsening lung function.39 In this study, the effect of BMI on FEF<sub>25–75</sub> and FEF<sub>25–75</sub>/FVC seems to be more pronounced from BMI 20 to 30, then from BMI 30 to 40 (figure 3).
Also, obesity is a complex chronic condition with varied patterns of fat depositions as well as many systemic and behavioural associations extending beyond mechanical effects of adipose tissue. Finally, even though multivariable modelling was used to account for possible confounding, it is understood that variables not available or missing variables in this data set may result in residual confounding.

In conclusion, increased BMI is associated with lower lung volumes, lesser emphysema and air trapping. The FEF_{25-75}/FVC ratio, as a dysanapsis ratio, seems to quantify the physiological impact of obesity on the COPD phenotype and is independently associated with COPD exacerbations and mortality. BMI affects the COPD phenotype in a manner that has similarities to CWS, which could provide a possible mechanistic basis for aspects of the BMI paradox seen in COPD.

Author affiliations
1Department of Medicine, University of Iowa, Iowa City, Iowa, USA
2Division of Pulmonary, Critical Care and Occupational Medicine, University of Iowa, Iowa City, Iowa, USA
3Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
4Division of Pulmonary and Critical Care Medicine, Temple University, School of Medicine, Philadelphia, Pennsylvania, USA
5Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland, USA
6Department of Electrical and Computer Engineering, University of Iowa, Iowa City, Iowa, USA
7The Iowa Institute for Biomedical Imaging, University of Iowa, University of Iowa, Iowa City, Iowa, USA
8Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama, Birmingham, Alabama, USA
9Department of Radiology, University of Iowa, Iowa, USA

Collaborators Administrative Centre: James D Crapo, MD, PhD; Edwin K Silverman, MD, PhD (PI); Barry J Make, MD; Elizabeth A Regan, MD, PhD. Genetic Analysis Centre: Terri Beaty, PhD; Ferdouse Begum, PhD; Robert Busch, MD; Peter J Castaldi, MD, MSc; Michael Cho, MD; Dawn L DeMeo, MD, MPH; Adel R Boueiz, MD; Marilyn G Foreman, MD; Eitan Halper-S tromberg; Nidia N Hansel, MD, MPH; Megan E Hardin, MD; Lyrsta P Hayden, MD, MSc; Craig P Hersh, MD; MPH; Jacqueline Helmanaki, MS, MPH; Brian D Hobbs, MD; John E Hokanson, MPH, PhD; Han Laird, PhD; Christoph Lange, PhD; Sharon M Lutz, PhD; Merryl Norman McDonald, PhD; Margaret M Parker, PhD; Dandi Giao, PhD; Elizabeth A Regan, MD, PhD; Stephanie Santorico, PhD; Edwin K Silverman, MD, PhD; Emily S Wan, MD; Sungho Won. Imaging Centre: Mustafa Al Qaisi, MD; Harvey O Coxson, PhD; Teresa Gray, MeiLan K Han, MD, MS; Eric A Hoffman, PhD; Stephen Humphries, PhD; Francine L Jacobson, MD, PhD; Philip F Judy, PhD; Ella A Kazerouni, MD; Alex Kluber; David A Lynch, MD; John D Newell, Jr, MD; Elizabeth A Regan, MD, PhD; James C Ross, PhD; Paul San Jose Estepar, PhD; Joyce Schroeder, MD; J ered Sieren; Douglas Stinson; Berend C Stoel, PhD; Juerg Tschirren, PhD; Edwin Van Beek, MD, PhD; Bram van Ginneken, PhD; Eva van Rikxoort, PhD; George Washko, MD; Carla G Wilson, MS. PFTQA Center, Salt Lake City, UT: Robert Jensen, PhD. Data Coordinating Center and Biostatistics, National Jewish Health, Denver, CO: Douglas Everett, PhD, Jim Crowe, PhD; Camille Moore, PhD; Matt Strand, PhD; Carla G Wilson, MS. Epidemiology Core, University of Colorado Anschutz Medical Campus, Aurora, CO: John E Hokanson, MPH, PhD; John Hughes, PhD; Gregory Kinney, MPH; Sharon M Lutz, PhD; Katherine Prattte, MS, PhD; Kendra A Young, PhD; Ann Arbor VA: Jeffrey L Curtis, MD; Carlos H Martinez, MD, MPH; Perry G Pernicone, MD. Baylor College of Medicine, Houston, TX: Nicola Hanania, MD, MS, Philip Alapat, MD; Mustafa Atik, MD; Venkata Bandi, MD; Aladin Boriek, PhD; Kalpatra Gunupudi, MD; Elizabeth Gu, MD; Arun Nachiappan, MD; Amit Parulekar, MD. Brigham and Women’s Hospital, Boston, MA: Dawn L DeMeo, MD, MPH; Craig Hersh, MD, MPH; Francine L Jacobson, MD, MPH; George Washko, MD. Columbia University, New York, NY: R Graham Barr, MD, DrPH; John Austin, MD; Bellinda D’Souza, MD; Gregory D N Pearson, MD; Anna Rozenshtein, MD, MPH. FACR, Byron Thomashow, MD Duke University Medical Center, Durham, NC: Neil Macintyre, Jr, MD; H Page McAdams, MD, Lacey Washington, MD. Health Partners Research Institute, Minneapolis, MN: Charlene McEvoy, MD, MPH; Joseph Tashjian, MD, Hopkins University, Baltimore, MD: Robert Wise, MD; Robert Brown, MD; Nadia N Hansel, MD, MPH; Karen Horton, MD; Allison Lambert, MD, MHS; Nirupama Putcha, MD, MHS. Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Torrance, CA: Michael E DeBakey VAMC. Houston: Richard Casaburi, PhD, MD; Alessandra Adami, PhD; Matthew Budoff, MD; Hans Fischer, MD, Janos Porzapszki, MD; Harry Rossalter, PhD; William Stringer, MD, TX: Amir Sharafkhaneh, MD, PhD; Charlie Lan, DO, Minneapolis VA: More House School of Medicine, Atlanta, GA: Marilyn G Foreman, MD, MS; Eugene Berkowitz, MD, PhD; Gloria Westney, MD, MS; National Jewish Health, Denver, CO: Russell Bowler, MD, PhD; David A Lynch, MD. Reliant Medical Group, Worcester, MA: Richard Rosiello, MD; David Pace, MD. Temple University, Philadelphia, PA: Gerard Criner, MD; David Ciccoletti, MD; Francis Cordova, MD, Chandra Dass, DO; Gilbert D’Anzo, DO; Parag Desai, MD; Michael Jacobs, PharmD; Steven Kelsen, MD, PhD; Victor Kim, MD; James Mamary, MD; Nathaniel Marchetti, DO; Aditi Satti, MD; Kartik Shenoy, MD; RobertM Steiner, MD; Alex Swift, MD; Irene Swift, MD; Maria ElenaVega-Sanchez, MD. University of Alabama, Birmingham, AL: Mark Dransfield, MD; William Bailey, MD; Surya Bhatt, MD; Anand Iyer, MD; Hrudaya Nuth, MD; J Michael Wells, MD. University of California, San Francisco, CA: Joe Ramdell, MD; Paul Friedman, MD; Xavier Soler, MD, PhD; AndrewWein, MD. Universityof Iowa, Iowa City, IA: Alejandro P Comellas, MD; John Newell, Jr, Brad Thompson, MD. University of Michigan, Ann Arbor, MI; MeiLan K Han, MD, MS; Ella A Kazerouni, MD, MS; Carlos H. Martinez, MD, MPH. University of Minnesota, Minneapolis, MN: Joanne Billings, Billings, Abbie Begnaud, MD; Tadashi Allen, MD. University of Pittsburgh, Pittsburgh, PA: Frank Scurba, MD; Jessica Bon, MD; Divyavad Chandra, MD, MSc; CarlFuhrman, MD; Joel Weisdorf, MD, MPH. University of Texas Health Science Center at San Antonio, San Antonio, TX: Antonio Anzueto, MD; Sandra Adams, MD, Diego Masselli-Caceres, MD; Mario E Ruiz, MD. Contributors Conception and design: EA, APC, ME. Analysis and interpretation: EA, APC, RMR, VK, RGB, SF, SPB, RRB, JDN, EAH and ME. Drafting the manuscript: EA and ME. Review of the manuscript for important intellectual content: EA, APC, RMR, VK, RAW, RGB, SF, SPB, RRB, JZ, JDN, EAH and ME. Funding The project described was supported by award number R01HL089897 and award number R01HL089856 from the National Heart, Lung and Blood Institute. Competing interests None declared.

Ethics approval Each study site received Institutional Review Board approval to participate in the study.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

© Article author(s) (or their employer(s)) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES


Higher BMI is associated with higher expiratory airflow normalised for lung volume (FEF25 –75/FVC) in COPD

Eric Abston, Alejandro Comellas, Robert Michael Reed, Victor Kim, Robert A Wise, Roy Brower, Spyridon Fortis, Reinhard Beichel, Surya Bhatt, Joseph Zabner, John Newell, Eric A Hoffman and Michael Eberlein

BMJ Open Resp Res 2017 4:
doi: 10.1136/bmjresp-2017-000231

Updated information and services can be found at: http://bmjopenrespres.bmj.com/content/4/1/e000231

These include:

References
This article cites 40 articles, 11 of which you can access for free at: http://bmjopenrespres.bmj.com/content/4/1/e000231#BIBL

Open Access
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Chronic obstructive pulmonary disease (28)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/